UK Advertising Watchdog Bans Online Promotion of Weight Loss Drugs

Online pharmacies are now prohibited from advertising weight loss drugs directly to the public in the United Kingdom, according to a crackdown by the Advertising Standards Authority (ASA). This action follows a series of complaints about advertisements that critics argued preyed on insecurities related to weight.

UK law generally forbids the advertising of prescription-only medicines to the public and the promotion of drugs not authorized by health regulators. However, investigations by the ASA previously found that some pharmacies were either openly violating these rules or exploiting loopholes to promote weight loss medications.

In a related development, pharmaceutical giant Eli Lilly faced criticism for an advertising campaign aired on Channel 4. The campaign's central message was that "obesity is a disease." While the advertisements did not name a specific drug, thereby adhering to UK advertising regulations, concerns were raised that the campaign indirectly fueled interest in prescription medications.

The ASA has now released new guidelines specifically for advertisements concerning weight loss treatments, aiming to establish clear precedents for advertisers. Catherine Drewett, Investigations Manager at the ASA, stated that the rapid development of these treatments presents new challenges for regulators. She emphasized that these powerful medicines should not be advertised in a way that could put individuals at risk, and that oral weight loss medicines, similar to prescription injections, cannot be advertised to the public.

Recent rulings by the ASA have targeted online pharmacies such as Simple Online Pharmacy and Pharmacy Online for promoting unbranded oral weight loss drugs through social media and website content. For instance, an advertisement for Simple Online Pharmacy invited consumers to join a waitlist for a "new oral weight loss treatment." This occurred shortly before the UK approved its first oral GLP-1 treatment for weight management, a tablet version of the popular drug Wegovy.

Pharmacy Online was also reprimanded for promoting an unnamed weight loss pill via website pop-ups and social media after it had been licensed as a prescription-only drug. These rulings are part of a broader regulatory effort against what the ASA describes as "irresponsible" marketing practices.

Further rulings were issued against MedExpress, Juniper, and The Care Pharmacy. The ASA found that even when specific drugs were not named, the overall impression created by the advertisements allowed consumers to identify them as prescription-only weight loss medicines. The ASA also stated that advertisements should avoid imagery of injection pens or phrases like 'reduced appetite and cravings,' as these can imply the promotion of prescription-only medication.

Experts suggest that the ban on advertising prescription-only drugs protects the public from commercial pressures, promotes safe and regulated prescribing, and discourages the medicalization of everyday concerns that might be addressed through lifestyle changes.

Last year, the ASA issued nine rulings that allowed pharmacies to mention weight loss injections on their websites, provided they were not featured on homepages and the term 'weight loss injections' was not used. Treatments were to be marketed as part of a broader service, including consultation and prescription, rather than as standalone products.

The ASA confirmed receiving multiple complaints about the Eli Lilly campaign that aired during The Great British Bake Off, but noted that these complaints were being handled by another regulator as they involved a pharmaceutical company's campaign rather than a specific medication.

The Medicines and Healthcare products Regulatory Agency (MHRA) has commended the ASA's swift action against rule-breaking advertisements. Julian Breach, the MHRA's interim executive director of healthcare, stated that all organizations promoting medicines must comply with advertising regulations designed to protect patient safety. He added that stimulating consumer demand for new prescription medicines is not permitted and that the MHRA takes breaches of advertising rules for prescription-only medicines very seriously, reserving the right to use its full range of regulatory powers.

Potential consequences for violations include fines and court proceedings. Breaches referred to the General Pharmaceutical Council can also lead to disciplinary actions against pharmacies and their personnel.

The effectiveness of these new rulings in curbing the illegal sale and promotion of weight loss drugs remains a key question, especially given that an estimated 2.5 million Britons are thought to be using these medications, with most paying privately due to limited NHS access.